Endocrine Testing Market Size & Share 2026-2035

Endocrine Testing Market Size

The global endocrine testing market was estimated at USD 3.4 billion in 2025. The market is expected to grow from USD 3.6 billion in 2026 to USD 7.4 billion in 2035, at a CAGR of 8.2% during the forecast period, according to the latest report published by Global Market Insights Inc.

Endocrine testing refers to a range of diagnostic procedures and laboratory analyses designed to assess the functioning of the endocrine system, which regulates hormonal balance in the body. This testing involves the measurement of hormone levels, metabolites, or glandular function to diagnose and monitor conditions such as thyroid disorders, diabetes, adrenal insufficiency, growth abnormalities, and reproductive health issues.

The rising prevalence of endocrine disorders is expected to fuel the industry's growth. Abbott, Thermo Fisher SCIENTIFIC, BECKMAN COULTER, BIO RAD, and Roche are among the leading players operating in the market. These players mainly focus on service innovation, geographic expansion, research and development, and collaboration with local or regional healthcare providers, among other factors.

The market has increased from USD 2.5 billion in 2022 to USD 3.1 billion in 2024, with a historic growth rate of 10.8%. The rising prevalence of endocrine disorders such as diabetes, thyroid dysfunction, and obesity has been a key driver for the growth of the endocrine testing market, as these conditions require regular screening, diagnosis, and long‑term monitoring through hormone and metabolic tests. Diabetes remains one of the most widespread endocrine disorders globally, with a growing burden of undiagnosed cases prompting increased demand for blood glucose, HbA1c, and insulin‑related testing. According to the World Health Organization (WHO), in 2022, 1 in 8 adults worldwide were living with obesity, significantly increasing the risk of diabetes and other endocrine abnormalities. Furthermore, the International Diabetes Federation (IDF) estimated that approximately 589 million adults were living with diabetes globally in 2024, representing about 1 in 9 adults, with projections showing continued growth over the coming decades. These trends underline the expanding patient pool requiring endocrine testing, thereby strongly supporting market growth.

Additionally, supportive government funding initiatives have played a crucial role in driving the growth of the endocrine testing market, as public health authorities increasingly prioritize early diagnosis, disease monitoring, and preventive care for endocrine disorders. Governments across developed and emerging countries expanded investments in national screening programs for diabetes, thyroid disorders, and obesity‑related complications, which directly increased the adoption of endocrine diagnostic tests. Funding support for public hospitals, diagnostic laboratories, and primary healthcare centers enabled wider access to hormone testing, particularly in underserved and rural populations. In addition, government‑backed healthcare reimbursement frameworks, subsidies for chronic disease management, and investments in laboratory infrastructure and automation have encouraged healthcare providers to expand endocrine testing capabilities, thereby strengthening market demand and supporting long‑term market growth.

Endocrine Testing Market Trends

Rapid technological advancements are driving innovation in the endocrine testing market, enabling hospitals, diagnostic laboratories, and specialty clinics to manage complex hormone testing workflows, high testing volumes, and long‑term monitoring of chronic endocrine disorders with greater accuracy and efficiency.

• Advances in high‑sensitivity assay technologies, automated immunoassay platforms, and AI‑enabled analytics are significantly improving the detection and quantification of endocrine biomarkers. For instance, Roche’s Elecsys immunoassay portfolio delivers highly specific hormone assays with improved analytical sensitivity, supporting standardized and reliable endocrine testing across clinical settings.
• The growing adoption of liquid chromatography–tandem mass spectrometry (LC‑MS/MS) is transforming endocrine testing by enabling highly specific, multiplexed hormone measurements, particularly for steroid hormones, vitamin D metabolites, and low‑concentration sex hormones. LC‑MS/MS reduces cross‑reactivity and analytical interference commonly seen in traditional immunoassays, improving diagnostic confidence in complex cases such as congenital adrenal hyperplasia or polycystic ovary syndrome. Thermo Fisher SCIENTIFIC and SCIEX provide advanced LC‑MS/MS platforms optimized for routine clinical endocrinology workflows.
• Integration of fully automated, high‑throughput endocrine analyzers with laboratory information systems (LIS) allows seamless data capture, sample tracking, and result reporting, reducing manual handling and turnaround times. Platforms such as Abbott’s Alinity systems and Siemens Healthineers’ Atellica Solution support broad endocrine assay menus, automated sample management, and real‑time quality control, enabling laboratories to scale testing capacity while maintaining consistency and regulatory compliance.
• As the burden of endocrine disorders continues to rise globally and healthcare systems prioritize early diagnosis, precision medicine, and chronic disease management, technological innovation remains a key factor accelerating the adoption of advanced, scalable, and data‑centric endocrine testing solutions across hospital, reference laboratory, and point‑of‑care settings.

Endocrine Testing Market Analysis

Based on test type, the market is segmented into human chorionic gonadotropin hormone test, thyroid stimulating hormone test, insulin test, progesterone test, luteinizing hormone test, prolactin test, and other test types. The human chorionic gonadotropin hormone test segment accounted for a dominant market share of 31.1% in 2025, driven by expanding clinical adoption and growing preference for rapid, non‑invasive diagnostic methods. The segment is expected to reach USD 2.2 billion by 2035, growing at a CAGR of 7.7% during the forecast period.

• The human chorionic gonadotropin (hCG) hormone test dominates the endocrine testing market due to its extensive use in pregnancy detection, fertility treatment monitoring, and oncology‑related diagnostics. High testing frequency, widespread adoption in hospitals and diagnostic laboratories, and strong demand from point‑of‑care and over‑the‑counter pregnancy tests collectively reinforce its leading market position.
• The thyroid stimulating hormone test segment is projected to expand at 8.7% CAGR to reach USD 2.3 billion by 2035. The thyroid stimulating hormone (TSH) test represents a key segment, driven by the high prevalence of thyroid disorders and routine screening practices. Its role as a primary diagnostic and monitoring tool for thyroid dysfunction supports steady demand across primary care, hospital laboratories, and endocrine specialty clinics.
• The insulin test segment is projected to expand at 9% CAGR to reach USD 982.8 million by 2035. The insulin test supports the assessment of metabolic disorders, particularly for diagnosing insulin resistance and specific diabetes conditions. While lower in volume than glucose‑based tests, its increasing use in advanced metabolic evaluation and personalized diabetes management contributes to moderate and consistent market growth.
• The progesterone test segment is projected to expand at 8.5% CAGR to reach USD 767.7 million by 2035. Progesterone testing is primarily used in fertility assessment and pregnancy monitoring, especially within assisted reproductive technology and gynecology settings. Rising infertility rates and increasing utilization of fertility treatments continue to support its niche, but growing demand within endocrine diagnostics.
• The luteinizing hormone test segment is projected to expand at 7.8% CAGR to reach USD 494 million by 2035. The luteinizing hormone (LH) test is widely used to evaluate ovulatory function and reproductive health disorders. Growing awareness of fertility planning and expanded access to clinical and home‑based ovulation testing solutions are driving increased adoption of LH assays.
• The prolactin test segment is projected to expand at 7.2% CAGR to reach USD 372.8 million by 2035. Prolactin testing is utilized to diagnose pituitary disorders, infertility, and menstrual irregularities. Although a lower‑volume segment, its clinical importance in endocrine and reproductive health ensures stable demand in hospital and specialty endocrine care settings.
• The other test types segment is projected to expand at 6.8% CAGR to reach USD 278.5 million by 2035. Other endocrine tests, including cortisol, ACTH, growth hormone, and parathyroid hormone assays, address specialized diagnostic needs. These tests typically involve lower testing volumes but higher analytical complexity, supporting demand in tertiary care hospitals and specialized laboratories.

Based on technology, the market is segmented into immunoassay, mass spectroscopy, chromatography, nucleic acid based, and other technologies. The immunoassay segment is projected to expand at 7.7% CAGR to reach USD 2.8 billion by 2035.

• Immunoassay is the dominant technology in the endocrine testing market due to its high sensitivity, specificity, cost‑effectiveness, and compatibility with high‑throughput automation. It is widely used across hospitals and diagnostic laboratories for routine hormone tests, particularly high‑volume assays such as hCG, TSH, and progesterone. The availability of automated platforms, rapid turnaround times, and broad regulatory acceptance continues to reinforce immunoassays as the preferred technology for endocrine diagnostics.
• The mass spectroscopy segment is projected to expand at 9% CAGR to reach USD 2 billion by 2035. Mass spectroscopy, particularly LC‑MS/MS, serves as a high‑precision technology for complex and low‑concentration hormone measurements. It is increasingly adopted for specialized testing, such as steroid hormones and vitamin D, where analytical accuracy is critical. Despite higher costs and operational complexity, mass spectroscopy is gaining traction in reference laboratories and advanced clinical settings.
• The chromatography segment is projected to expand at 8.7% CAGR to reach USD 1.2 billion by 2035. Chromatography is used as a supportive and preparatory technique in endocrine testing, often in combination with mass spectroscopy. Its role is particularly important in separating complex hormone mixtures and improving analytical specificity. While not a stand‑alone dominant technology, chromatography remains essential for specialized and research‑oriented endocrine applications.
• The nucleic acid based segment is projected to expand at 7.4% CAGR to reach USD 718.9 million by 2035. Nucleic acid–based technologies play a limited role in endocrine testing, primarily confined to genetic or molecular investigations related to endocrine disorders. These technologies are not widely used for routine hormone quantification but are gaining relevance in research and personalized medicine contexts where genetic predisposition to endocrine diseases is assessed.
• The other technologies segment is projected to expand at 7.9% CAGR to reach USD 597.2 million by 2035. Other technologies include biosensors and emerging point‑of‑care platforms designed for rapid hormone testing. These solutions address niche needs such as decentralized testing and home‑based diagnostics, but currently account for a smaller share of the overall market compared to immunoassay‑based systems.

Based on end use, the market is segmented into clinical laboratories, hospitals, diagnostic centers, and other end users. The clinical laboratories segment dominates the market with revenue of around USD 1.6 billion in 2025.

• Clinical laboratories dominate the endocrine testing market due to their ability to handle high testing volumes, standardized workflows, and advanced diagnostic infrastructure. These laboratories serve as primary hubs for routine and specialized hormone testing, including high‑frequency assays such as hCG, TSH, and insulin. Strong automation capabilities, broad test menus, and centralized processing enable clinical laboratories to deliver cost‑effective, accurate, and scalable endocrine diagnostic services, reinforcing their leading market position.
• The hospitals segment is projected to expand at 7.7% CAGR to reach USD 2.8 billion by 2035. Hospitals represent a significant end‑user segment, driven by the need for timely endocrine testing in inpatient, outpatient, and emergency care settings. Demand is supported by integrated laboratory services, higher acuity patient populations, and increased screening for metabolic and hormonal disorders during hospital admissions. Hospitals also play a key role in managing complex endocrine conditions that require continuous monitoring and multidisciplinary care.
• The diagnostic centers segment is projected to expand at 7.9% CAGR to reach USD 622.2 million by 2035. Diagnostic centers are experiencing steady growth as end users, particularly in urban and semi‑urban regions. These centers focus on outpatient testing, preventive health check‑ups, and specialized hormone panels, benefiting from rising patient awareness and demand for convenient diagnostic access. Expansion of private diagnostic chains and adoption of automated testing platforms continue to support the segment’s market presence.
• The other end users segment is projected to expand at 7.2% CAGR to reach USD 259.5 million by 2035. Other end users include fertility clinics, research institutions, and point‑of‑care settings. Fertility centers, in particular, contribute to demand for reproductive hormone testing such as hCG, progesterone, and LH. While this segment accounts for a smaller market share, increasing specialization and niche testing applications support its continued relevance within the endocrine testing ecosystem.

 North America Endocrine Testing Market

North America endocrine testing industry accounted for USD 1.5 billion in revenue in 2025 and is predicted to witness substantial market growth over the analysis timeline.

• The U.S. market was valued at USD 1.02 billion and USD 1.12 billion in 2022 and 2023, respectively. The market size reached USD 1.33 billion in 2025, growing from USD 1.23 billion in 2024, and is anticipated to grow at a CAGR of 7.2% from 2026 to 2035.
• The North America endocrine testing industry is driven by a high burden of chronic endocrine disorders, advanced healthcare infrastructure, and early adoption of high‑complexity diagnostic technologies. The region demonstrates strong demand for routine and specialized endocrine assays, including HbA1c, thyroid panels, adrenal hormone testing, and fertility diagnostics. Extensive screening programs, favorable reimbursement frameworks, and widespread access to automated immunoassay and mass spectrometry platforms support consistent testing volumes across hospital and reference laboratory settings.
• Rising disease prevalence continues to underpin market expansion. According to the U.S. Centers for Disease Control and Prevention (CDC), 40.1 million people, approximately 12% of the U.S. population, were living with diabetes in 2023, with a large proportion requiring continuous biochemical monitoring. This sustained disease burden is accelerating demand for high‑throughput, standardized endocrine testing solutions that support long‑term disease monitoring and population‑level management.

Europe Endocrine Testing Market

Europe accounted for a significant share of the global endocrine testing industry and was valued at USD 894 million in 2025.

• Europe’s endocrine testing industry is shaped by an aging population, strong public healthcare systems, and increasing emphasis on early diagnosis and chronic disease management. National screening initiatives for diabetes and thyroid dysfunction, combined with centralized laboratory networks and stringent quality standards, continue to drive consistent demand for endocrine diagnostics across Western and Northern Europe. Adoption of high‑specificity assays and laboratory automation is particularly strong in tertiary care and reference laboratory environments.
• From a disease perspective, endocrine disorders remain a growing public health challenge. Eurostat data indicates that 50.6% of adults aged 16 years or older in the European Union were overweight or obese in 2022, significantly increasing the risk of type 2 diabetes and related hormonal imbalances. This epidemiological trend is reinforcing long‑term demand for metabolic and endocrine testing, particularly for glucose metabolism, thyroid function, and lipid‑associated hormonal disorders.

Asia Pacific Endocrine Testing Market

The Asia Pacific market accounted for a substantial share of the market and was valued at USD 737.7 million in 2025.

• The Asia Pacific market is experiencing rapid growth, driven by expanding healthcare access, urbanization, and a sharp rise in lifestyle‑related endocrine disorders. Countries such as China, India, and Southeast Asian nations are witnessing increasing diagnostic demand as governments invest in laboratory infrastructure, chronic disease screening programs, and decentralized testing models. Growing private diagnostics networks and medical tourism further contribute to rising endocrine test volumes.
• The scale of disease prevalence provides a strong structural growth base. According to the International Diabetes Federation (IDF), India alone had approximately 89.8 million adults living with diabetes in 2024, positioning the country as one of the largest contributors to global endocrine testing demand. This escalating disease burden is accelerating adoption of reliable, scalable endocrine testing solutions across both urban and semi‑urban healthcare settings.

Latin America Endocrine Testing Market

The Latin America market is anticipated to exhibit remarkable growth during the analysis period.

• In Latin America, the endocrine testing industry is expanding as healthcare systems respond to rising non‑communicable disease prevalence and improved access to diagnostic services. Public health initiatives targeting diabetes and metabolic disorders, combined with expanding private laboratory chains in countries such as Brazil and Mexico, are driving increased utilization of endocrine tests. However, variability in healthcare funding and access creates uneven adoption across the region.
• Disease prevalence remains a major catalyst. According to the Pan American Health Organization (PAHO), 67.5% of adults in Latin America and the Caribbean were overweight or obese in 2022, sharply increasing the prevalence of diabetes and metabolic disorders. This growing epidemiological burden is strengthening long‑term demand for endocrine testing, particularly for glucose regulation and thyroid screening in primary and secondary care settings.

Middle East and Africa Endocrine Testing Market

The Middle East and Africa  market is expected to experience substantial growth over the analysis timeframe.

• The Middle East and Africa endocrine testing industry is shaped by contrasting dynamics, with rapid demand growth in Gulf Cooperation Council (GCC) countries and gradual expansion in parts of Africa. Rising healthcare investments, modernization of laboratory infrastructure, and increasing awareness of chronic disease management are supporting the adoption of endocrine diagnostics, particularly in urban centers and private healthcare facilities across the Middle East.
• From a disease standpoint, the region faces one of the world’s fastest‑growing diabetes burdens. According to the International Diabetes Federation (IDF), 1 in 6 adults in the Middle East and North Africa (MENA) regions, approximately 85 million people, were living with diabetes in 2024, representing the highest regional prevalence globally. This high disease burden is driving sustained demand for endocrine testing focused on diabetes management, obesity‑related hormonal disorders, and metabolic risk assessment.

Endocrine Testing Market Share

• The endocrine testing industry is highly specialized, with leading players such as Abbott, Thermo Fisher SCIENTIFIC, BECKMAN COULTER, BIO RAD, and Roche, collectively accounting for approximately 55% of the global market share. These companies benefit from strong diagnostic expertise, extensive assay portfolios, and long‑standing relationships with hospitals, clinical laboratories, and reference lab networks. Their offerings span high‑volume immunoassays, advanced analytical platforms, quality control solutions, and integrated testing systems supporting hormone diagnostics across diabetes, thyroid disorders, fertility, and metabolic disease management. Their technologies are widely adopted across large, centralized laboratories, hospital‑affiliated labs, and independent diagnostic centers, reinforcing their competitive positioning and market leadership.
• The competitive landscape is characterized by continuous innovation in assay sensitivity, automation, and analytical accuracy, alongside advancements in areas such as high‑throughput immunoassay platforms, LC‑MS/MS systems, data integration, and workflow optimization. Strategic initiatives, including product portfolio expansion, technology upgrades, global distribution partnerships, and targeted acquisitions, remain key growth strategies for these vendors. Collectively, these efforts enable market leaders to expand geographic reach, address evolving regulatory requirements, and support the increasing complexity and volume demands of endocrine testing worldwide.

Endocrine Testing Market Companies

A few of the prominent players operating in the global endocrine testing industry include:

• Abbott          
• Autobio                   
• BECKMAN COULTER           
• BIO RAD                 
• Diasorin                  
• DRG International              
• Merck           
• Monobind                
• OuidelOrtho            
• Roche           
• SCIEX          
• SIEMENS Healthineers                  
• Snibe Diagnostic                
• Thermo Fisher SCIENTIFIC            
• TOSOH BIOSCIENCE          

• Abbott

Abbott holds a strong position in the endocrine testing market through its broad immunoassay portfolio and automated Alinity platforms, supporting high‑volume hormone testing such as hCG, TSH, insulin, and fertility markers. The company benefits from deep penetration across clinical laboratories and hospitals, strong global distribution, and continuous investment in assay accuracy, workflow efficiency, and scalable testing solutions for chronic disease management.

• Roche

Roche is a leading player in the endocrine testing market, driven by its strong portfolio of immunoassay‑based diagnostics offered through the Elecsys and cobas platforms. The company is widely recognized for its comprehensive hormone test menu, including hCG, thyroid, fertility, and other key endocrine markers, which are extensively adopted in hospitals and clinical laboratories worldwide. Roche’s competitive strength lies in high assay reliability, clinical standardization, workflow automation, and seamless integration across laboratory systems, making it a preferred partner for high‑throughput and routine endocrine testing environments.

• BECKMAN COULTER

BECKMAN COULTER maintains a solid presence in the endocrine testing market with its automated immunoassay analyzers and integrated laboratory workflow solutions. The company supports a wide range of routine endocrine tests, including thyroid and reproductive hormones, and is well-positioned in hospital‑based and centralized laboratory environments. Its emphasis on reliability, throughput, and operational efficiency strengthens its competitive standing.

Endocrine Testing Industry News:

• In January 2024, Agilent Technologies announced the launch of its new PathHunter Testing System, designed to enhance the accuracy and efficiency of endocrine disorder diagnostics. This innovative system integrates advanced chemiluminescent technology with high-throughput capabilities, enabling precise measurement of hormone levels in various biological samples.
• In September 2025, DiaSorin launched the LIAISON TSH‑R Ab immunoassay, which was designed to improve the diagnosis and monitoring of Graves’ disease and autoimmune thyroid disorders. The assay expanded DiaSorin’s specialized endocrine testing menu on its LIAISON platform.

The global endocrine testing market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Human chorionic gonadotropin (HCG) hormone test
• Thyroid stimulating hormone (TSH) test
• Insulin test
• Progesterone test
• Luteinizing hormone (LH) test
• Prolactin test
• Other test types

Market, By Technology

• Immunoassay
• Mass spectroscopy
• Chromatography
• Nucleic acid based
• Other technologies

Market, By End Use

• Clinical laboratories
• Hospitals
• Diagnostic centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE